Aitia

BREAKING NEWS: Aitia will collaborate with Orion Corporation to uncover novel drug targets and develop new therapies to fight cancer. As part of the collaboration, Aitia will utilize Orion’s pre-clinical and clinical data to build Gemini Digital Twin models that will help answer translational questions and validate unique approaches across multiple indications. This collaboration represents a fusion of Aitia's advanced AI capabilities with Orion's expertise in oncology research and development. Cancer is a global health issue, impacting millions of people, and new cases are expected to rise significantly, driven by population growth and aging. By working together, Aitia and Orion aim to unlock deeper insights into the complex biology of cancer, ultimately accelerating the development of novel therapies that could significantly improve patient outcomes.   Read more about this collaboration in our press release:  https://lnkd.in/gXh2AYuD #AI #DIGITALTWINS #ONCOLOGY #INNOVATION

Starting now: Learn how AI is transforming drug discovery from our CEO Colin Hill and other industry experts at the Genetic Engineering & Biotechnology News virtual summit - it's free and live: https://lnkd.in/eeY6BkDC #AI #DigitalTwins #DrugDiscovery #DrugDevelopment

Breaking News: Aitia and Servier Pharmaceuticals are expanding their collaboration to tackle one of medicine's biggest challenges: brain cancer. Using Aitia's Gemini Digital Twins technology, which analyzes millions of data points from patient tissues, we aim to discover new treatments for gliomas - tumors that affect over 190,000 people worldwide each year. This marks our fourth collaboration with Servier, building on our existing work in multiple myeloma, pancreatic cancer and Parkinson's disease. Together, we're combining Servier's expertise in drug development with our AI-driven approach to unlock new possibilities for patients. Learn more about this collaboration:  https://prn.to/4e1MNzK #BrainCancer #DrugDiscovery #AI #DigitalTwins

Our team is at CTAD Clinical Trials on Alzheimer's Disease's in Madrid this week sharing research on improving Alzheimer's detection. Visit Poster #135 to discuss with Joseph Donahue how machine learning could make diagnosis more accessible and cost-effective for patients. #CTAD24 #AlzheimersDisease #MachineLearning #DigitalTwins #HealthcareInnovation #AI Jeanne Latourelle So-Youn Shin Wenjun Zhu LI SUN, Jerome Windsor Ruby Hsu John Dwyer Lammert Albers

How is AI reshaping drug discovery in 2024? Join our CEO Colin Hill tomorrow at the Genetic Engineering & Biotechnology News inaugural virtual summit 'The State of AI in Drug Discovery' for insights on AI's evolving role in biotechnology. Colin joins Simon Barnett (Dimension), Sabrina Yang, PhD (Empress Therapeutics/Flagship Pioneering) to examine the business landscape of AI-powered drug development. The event features the recent chemistry Nobel-Prize winner David Baker, PhD professor of biochemistry, HHMI investigator, and director of the Institute for Protein Design, University of Washington, as well as Najat Khan, PhD, Chief R&D and Chief Commercial Officer of Recursion and many others. Don’t miss Colin’s panel on October 30, 2024 at 9:20 AM PDT. Registration is free: https://lnkd.in/eeY6BkDC #AI #DigitalTwins #DrugDevelopment

Join us at CTAD Clinical Trials on Alzheimer's Disease (#CTAD24) in Madrid where our Chief Business Officer Joe Donahue will present new research on making Alzheimer's detection more accessible. Our team developed a machine-learning model that predicts brain changes using routine medical data, potentially reducing the need for scans and blood tests. Stop by Poster #135 to learn how this approach could help more patients access early diagnosis. October 29 - November 1, 2024 in Madrid, Spain #CTAD24 #AlzheimersDisease #MachineLearning #DigitalTwins #HealthcareInnovation #AI Jeanne Latourelle So-Youn Shin Wenjun Zhu LI SUN, Jerome Windsor Ruby Hsu John Dwyer Lammert Albers

We are teaming up with Orion Pharma Ltd to accelerate drug discovery and improve patient outcomes in oncology. Read more in James Waldron's Fierce Biotech article about how Aitia's Gemini Digital Twins will use Orion's pre-clinical and clinical data to uncover hidden disease drivers and hopefully, new treatments for patients. https://lnkd.in/eb_73EeP #AI #DigitalTwins #Cancer #DrugDevelopment

In the rapidly evolving landscape of AI in drug development, how can we distinguish between hype and genuine innovation? Our CEO Colin Hill will discuss this issue today at Biotech Alchemy’s 2024 Life Sciences Summit. Colin will be joined by a panel of experts including Mark Silverman, Director, Digital Lab and Omnichannel Strategy, Gastroenterology, AbbVie, Paul Buckman, Director, Online Media, FDA and Bob Pearson, Chair, The Next Solutions Group.    The panel will explore: ·   What are the real-world applications of AI in drug discovery today? ·    How is AI reshaping workflows in biotech and pharmaceutical research? ·    Where do we need to focus our efforts to maximize AI's potential in healthcare?   Don’t miss this event!    Panel: "The Role of AI in Biotech & Healthcare: Distinguishing Hype From Innovation" Date: Sept. 26, 9:50 a.m. - 10:45 a.m. EST Agenda: https://lnkd.in/e54kj2pF

Don't miss The Pistoia Alliance webinar on digital twins in pharma R&D tomorrow, Sept. 19 at 10 am ET. Learn how this technology enables more informed decisions and accelerates breakthrough drug development. Featuring Bruce Church, PhD, our Chief Mathematics Officer and EVP, Research and Early Development, alongside Julia Schueler from Charles River Laboratories. Sign up here: https://lnkd.in/g7Sna8YJ #DigitalTwins #DrugDevelopment #AI #Pharma